Although a clinical examination with comprehensive metabolite measurements is not feasible, an integrated evaluation of these few key metabolites and cytokines (especially CXCL10) in SARS-CoV-2-positive patients would allow for a practical and accurate risk assessment of the potential for severe outcomes in the early stages of infection. Here, CXCL10 is linked to infection.